BofA warns Fed risks policy mistake with early rate cuts
On Monday, H.C. Wainwright reaffirmed its Buy rating and $3.00 price target on RenovoRx Inc. (NASDAQ: RNXT) following the company’s strategic update and a fireside chat. With the stock currently trading at $0.91 and a market cap of $32.4 million, analysts see significant upside potential, with price targets ranging from $3.00 to $9.00. According to InvestingPro data, the stock has experienced a 29% decline year-to-date, potentially presenting an opportunity for investors. The biopharmaceutical company is on schedule with its Phase 3 TIGeR-PaC study for the treatment of locally advanced pancreatic cancer using its RenovoCath delivery system for gemcitabine.
RenovoRx announced that it is progressing towards completing the enrollment of 114 patients for the pivotal study within 2025. As of March 28, the study had reached 50 events, with the second interim analysis set to be triggered after the 52nd event. This analysis is anticipated to occur in the second quarter of 2025. Additionally, the TIGeR-PaC Data Monitoring Committee (DMC) is slated to conduct a futility analysis in the second half of 2025.
The company had previously reported encouraging results from the first interim analysis, which showed an overall survival (OS) of approximately 21.5 months for patients treated with RenovoCath delivered gemcitabine, as opposed to 15.5 months for the standard-of-care intravenous gemcitabine plus abraxane control arm. The safety profile was also favorable. InvestingPro analysis reveals that while the company maintains a strong current ratio of 4.1 and holds more cash than debt, it’s currently burning through cash rapidly - crucial factors for investors monitoring clinical-stage biotech companies.
During the recent fireside chat, Dr. Gregory Tiesi, a key opinion leader, spoke about the improved patient tolerability observed with RenovoCath’s delivery method compared to systemic therapy. He also noted the potential for the platform to administer various therapeutic agents.
The company has seen adoption of its technology by more than 10 medical institutions since receiving its first purchase orders in December, leading to quarterly revenues of $43,000. Looking ahead to 2025, RenovoRx’s management has provided guidance for revenues in the low six-figure digit range for the first quarter, with expectations for sequential quarter-over-quarter revenue growth for the rest of the year. Analysts tracked by InvestingPro anticipate sales growth of 22.3% in the current year. H.C. Wainwright has reiterated its Buy rating on RNXT stock, maintaining a 12-month price target of $3.00 per share. For investors seeking deeper insights, InvestingPro offers 8 additional key tips and comprehensive financial metrics to better evaluate RNXT’s investment potential.
In other recent news, RenovoRx has reported its financial results for 2024, highlighting the generation of its first revenue from the RenovoCath device, amounting to approximately $43,000 in the fourth quarter. The company anticipates revenue to rise to the low six-figure range in the first quarter of 2025, with further increases expected throughout the year. RenovoRx ended 2024 with a cash balance of $7.2 million and raised an additional $12.1 million in February 2025. The company is advancing its Phase III TIGeR-PaC clinical trial, with full enrollment expected in 2025. RenovoRx has been recognized for its TAMP therapy platform, receiving honors at the Society of Interventional Radiology 2025 Annual Scientific Meeting. The platform is currently being evaluated for its effectiveness in treating locally advanced pancreatic cancer. Additionally, RenovoRx has initiated a public stock offering to fund its ongoing Phase III study and commercial activities for RenovoCath. The offering is managed by Titan Partners Group and will be conducted under a shelf registration statement filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.